Art. -Nr.: HY-B1011

Copy Link Print Information

Edoxudine

(Synonyms: EUDR)

Kundenbewertung

Based on 1 Customer Validation

Edoxudine is an antiviral active molecule and thymidine analog. Edoxudine is effective against herpes simplex virus.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.93%
CAS. Nr.: 15176-29-1
Formel: C₁₁H₁₆N₂O₅
Molecular Weight:256.26

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Edoxudine Chemical Structure

CAS. Nr.: 15176-29-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Edoxudine is an antiviral active molecule and thymidine analog. Edoxudine is effective against herpes simplex virus^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
Fibroblast	IC₅₀	115 μM Compound: le	Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells	[PMID: 8394933]
Hepatocyte	EC₅₀	29.2 μM Compound: 1e	Ability to reduce the viral DNA in HBV infected primary duck hepatocytes to 50% Ability to reduce the viral DNA in HBV infected primary duck hepatocytes to 50%	[PMID: 11585457]
HepG2 2.2.15	EC₅₀	>10 μg/mL Compound: 8	Antiviral activity against HBV infected in human 2.2.15 cell Antiviral activity against HBV infected in human 2.2.15 cell	[PMID: 20863701]
HFF	EC₅₀	0.6 μM Compound: le	Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells	[PMID: 8394933]
HFF	EC₅₀	0.9 μM Compound: le	Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells	[PMID: 8394933]
HFF	EC₅₀	1.5 μM Compound: le	Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells	[PMID: 8394933]
HFF	EC₅₀	66.4 μM Compound: le	Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells	[PMID: 8394933]
Huh-7	CC₅₀	>200 μg/mL Compound: 8	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 20863701]
Raji	EC₅₀	12.1 μM Compound: le	Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells	[PMID: 8394933]
Vero	CC₅₀	>780 μM Compound: Et-dU	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]
Vero	EC₅₀	13.3 μM Compound: Et-dU	Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	19.5 μM Compound: 1e	Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50% Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	2.1 μM Compound: Et-dU	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	32.7 μM Compound: 1e	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50% Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	37.4 μM Compound: Et-dU	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	390 μM Compound: 1e	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 ADVero cells by 50% Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 ADVero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	42.9 μM Compound: 1e	Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50% Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	48 μM Compound: Et-dU	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	58.5 μM Compound: 1e	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50% Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	780 μM Compound: 1e	Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50% Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50%	[PMID: 11585457]

In Vitro

Edoxudine has less effect on the viability of TK6:hsv cells compared to wild-type C7-10 cells, as evidenced by higher LC₅₀ value (175-200 μM, 125 μM, respectively)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 15176-29-1
Appearance Solid
Molecular Weight 256.26
Formel C₁₁H₁₆N₂O₅
Color White to light yellow
SMILES

O[C@H]1C[C@H](N2C(NC(C(CC)=C2)=O)=O)O[C@@H]1CO
Synonyms

EUDR
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 125 mg/mL (487.79 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (195.12 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9023 mL

19.5116 mL

39.0232 mL

5 mM

0.7805 mL

3.9023 mL

7.8046 mL

10 mM

0.3902 mL

1.9512 mL

3.9023 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (8.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kaul R, et al. [Penetration and action of edoxudine in vitro and in vivo]. Arzneimittelforschung. 1989 Mar;39(3):366-8. [Content Brief]

[2]. Mazzacano CA, et al. Evaluation of a viral thymidine kinase gene for suicide selection in transfected mosquito cells. Insect Mol Biol. 1995 May;4(2):125-34. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.9023 mL	19.5116 mL	39.0232 mL	97.5579 mL
	5 mM	0.7805 mL	3.9023 mL	7.8046 mL	19.5116 mL
	10 mM	0.3902 mL	1.9512 mL	3.9023 mL	9.7558 mL
	15 mM	0.2602 mL	1.3008 mL	2.6015 mL	6.5039 mL
	20 mM	0.1951 mL	0.9756 mL	1.9512 mL	4.8779 mL
	25 mM	0.1561 mL	0.7805 mL	1.5609 mL	3.9023 mL
	30 mM	0.1301 mL	0.6504 mL	1.3008 mL	3.2519 mL
	40 mM	0.0976 mL	0.4878 mL	0.9756 mL	2.4389 mL
	50 mM	0.0780 mL	0.3902 mL	0.7805 mL	1.9512 mL
	60 mM	0.0650 mL	0.3252 mL	0.6504 mL	1.6260 mL
	80 mM	0.0488 mL	0.2439 mL	0.4878 mL	1.2195 mL
	100 mM	0.0390 mL	0.1951 mL	0.3902 mL	0.9756 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Edoxudine

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

FDA Approved & Pharmacopeial Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

3D Diverse Fragment Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Edoxudine

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

FDA Approved & Pharmacopeial Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

3D Diverse Fragment Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Edoxudine Related Classifications

HY-B1011 Related Classifications